https://www.live-feeds.com/feed/lilly-sets-up-next-gen-obesity-battle-with-full-phase-3-retatrutide-dataContinuously updated, source-cited coverage. https://www.live-feeds.com/feed/lilly-sets-up-next-gen-obesity-battle-with-full-phase-3-retatrutide-datahttps://www.live-feeds.com/feed/lilly-sets-up-next-gen-obesity-battle-with-full-phase-3-retatrutide-data#u97268Sat, 03 Oct 2026 15:41:25 +0000Eli Lilly has released full phase 3 trial data for retatrutide, its experimental triple agonist weight-loss drug. In an 80-week trial, adults with type 2 diabetes taking the highest dose of retatrutide lost an average of 18.8% of their body weight, compared to 5.1% for the placebo group. Across trials, the drug delivered an average weight loss of 50 pounds, with some individuals losing up to 60 pounds. Additionally, Eli Lilly reported mid-stage trial results for EloraTZP, a combination of eloralintide and tirzepatide.Why it mattersRetatrutide is the first triple agonist of its kind to reach a